Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2009

Net earnings per diluted share from continuing operations rise 15 percent;
reach $0.78 for the quarter and $2.65 for fiscal year 2009

PALO ALTO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Varian Medical Systems
(NYSE: VAR) today is reporting net earnings from continuing operations of
$0.78 per diluted share in the fourth quarter of fiscal year 2009, up 15
percent from $0.68 in the year-ago quarter. Net earnings per diluted share
from continuing operations for the full fiscal year 2009 climbed to $2.65,
also up 15 percent from $2.31 in fiscal year 2008. The sale of the non-proton
therapy portion of the ACCEL business earlier in the year and its resulting
classification as a discontinued operation reduced net earnings per diluted
share by $0.01 to $0.77 for the quarter and by $0.10 to $2.55 for the fiscal
year.

Compared to the same periods in fiscal year 2008, fourth-quarter revenues grew
8 percent to $642 million and revenues for the full fiscal year 2009 rose by 7
percent to $2.2 billion. Net orders, including a large proton system order,
rose 4 percent for the quarter to $755 million and increased 3 percent for the
fiscal year to $2.4 billion. The fiscal 2009 year-ending backlog increased to
$2.1 billion, up 9 percent from the prior year. Excluding the proton therapy
order, the backlog was up 5 percent.

"Our company has encountered a challenging business environment in North
America, but we achieved excellent earnings growth for the quarter and the
fiscal year as a result of mix shifts towards newer higher margin oncology
products and services as well as successful ongoing initiatives to cut costs,"
said Tim Guertin, president and CEO of Varian Medical Systems. "Our Oncology
Systems and X-Ray Products businesses each contributed to solid revenue growth
for the quarter versus strong year-ago comparisons. Net orders increased with
the help of the company's first proton therapy system order and continued
demand for oncology products in international markets."

The company ended the fiscal year with $554 million in cash and cash
equivalents and $37 million of debt. During the fourth quarter, the company
spent $30 million to repurchase 700,000 shares of common stock. Throughout
the fiscal year, the company spent $101 million to repurchase 2.2 million
shares, which helped to reduce average diluted shares outstanding by 2.6
million from the prior year to 125 million. The company ended the quarter with
accounts receivable days sales outstanding of 81, an increase of seven days
from the year-ago quarter, but down two days from the third quarter of fiscal
year 2009.

Oncology Systems
Oncology Systems' fourth quarter revenues in fiscal year 2009 totaled $527
million, up 9 percent from the same period last fiscal year. Oncology
revenues for the fiscal year were $1.8 billion, up 8 percent from the fiscal
year 2008 total.

Fourth-quarter net orders were $570 million, down 7 percent with a 20 percent
decline in North America and 12 percent growth in international markets. Net
orders for the fiscal year rose to $1.9 billion, up 1 percent from last year,
with a 7 percent decline in North America and 11 percent growth in
international markets.

"Our Oncology Systems business is weathering a climate of uncertainty in
North America created by economic recession as well as the prospects of
healthcare reform and reimbursement cuts," Guertin said. "Meanwhile, we have
had a healthy year in the international oncology market. Oncology Systems
achieved solid revenue growth and improved its margins through increased sales
of software and services."

X-Ray Products
Fourth quarter revenues for the X-Ray Products business were $93 million, up
11 percent from the year-ago quarter, and revenues for the full fiscal year
were $332 million, up 9 percent from fiscal year 2008 levels. Compared to
corresponding periods in fiscal year 2008, X-Ray Products' fourth quarter net
orders rose 3 percent to $97 million, and fiscal year net orders rose 1
percent to $339 million.

"X-Ray Products orders and sales grew with the help of demand for its new line
of radiographic imaging panels," Guertin said. "Aftermarket X-ray tubes also
contributed to growth in orders and revenues for this segment. A strong focus
on cost control led to higher operating earnings for this business."

Other
The company's Other category, which is comprised of the Security and
Inspection Products business, the Varian Particle Therapy business, and the
Ginzton Technology Center, recorded fourth quarter revenues of $23 million,
down 16 percent from the year-ago period. Revenues for the fiscal year
totaled $85 million, down 9 percent from fiscal year 2008, principally as a
result of slower deployment of security systems.

Fourth-quarter net orders in the Other category were $89 million, up $68
million from the year-ago quarter with strong contributions from the particle
therapy and security businesses. As previously announced, the company was
awarded a $62 million contract by Skandion Kliniken following a public tender
to deliver the equipment for Sweden's first proton therapy system. "As is
common in these public tenders, this award is being challenged by a competitor
in Swedish courts, we believe that the award was proper and we booked the
order during the fourth quarter," Guertin said. Including this order, fiscal
year 2009 net orders for the Other category totaled $151 million, up $56
million from the fiscal year 2008 total.

Outlook
"Weak orders in the second half of fiscal year 2009 together with ongoing
uncertainty stemming from the recession, the healthcare reform movement and
proposed cuts in reimbursements in North America give us a cautious outlook
for fiscal year 2010," said Guertin. "We believe that for the first quarter
of fiscal year 2010 total company revenues could increase by three to four
percent over the prior year. Including a higher tax rate and a one-time
$0.02-per-share charge for a recently completed reduction in force, net
earnings per diluted share from continuing operations for the first quarter
could be in the range of $0.52 to $0.56. For the full fiscal year 2010, we
estimate that revenues and operating earnings could increase by four to five
percent over the fiscal year 2009 total and that net earnings per diluted
share from continuing operations could be in the range of $2.65 to $2.75."

Investor Conference Call
Varian Medical Systems is scheduled to conduct its fiscal year 2009 conference
call at 2 p.m. PT today. To hear a live webcast or replay of the call, visit
the investor relations page on the company's web site at
www.varian.com/investor where it will be archived for a year. To access the
call via telephone, dial 1-866-700-6067 from inside the U.S. or 1-
617-213-8834 from outside the U.S. and enter confirmation code 74581862. The
replay can be accessed by dialing 1-888-286-8010 from inside the U.S. or
1-617-801-6888 from outside the U.S. and entering confirmation code 40919568.
The telephone replay will be available through 5 p.m. PT, October 30, 2009.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading
manufacturer of medical devices and software for treating cancer and other
medical conditions with radiotherapy, radiosurgery, proton therapy, and
brachytherapy. The company supplies informatics software for managing
comprehensive cancer clinics, radiotherapy centers and medical oncology
practices. Varian is a premier supplier of tubes and digital detectors for
X-ray imaging in medical, scientific, and industrial applications and also
supplies X-ray imaging products for cargo screening and industrial inspection.
Varian Medical Systems employs approximately 5,100 people who are located at
manufacturing sites in North America, Europe, and China and approximately 79
sales and support offices around the world. For more information, visit
http://www.varian.com.

Forward-Looking Statements
Except for historical information, this news release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Statements concerning industry outlook, including growth drivers; the
company's future orders, revenues, backlog, or earnings growth; future
financial results; market acceptance of or transition to new products or
technology such as RapidArc, image-guided radiation therapy, stereotactic
radiosurgery, filmless X-rays, proton therapy, and security and inspection,
and any statements using the terms "expect," "could," "believe," "estimate,"
"outlook," or similar statements are forward-looking statements that involve
risks and uncertainties that could cause the company's actual results to
differ materially from those anticipated. Such risks and uncertainties include
the effect of economic conditions, including the current global recession; the
impact of health care reforms, and/or changes in third-party reimbursement
levels; credit availability for capital expenditures for cancer care; currency
exchange rates and tax rates; demand for the company's products; the company's
ability to develop and commercialize new products; the company's reliance on
sole or limited-source suppliers; the impact of reduced or limited demand by
sole purchasers of certain X-ray tubes; the company's ability to maintain or
increase operating margins; the impact of competitive products and pricing;
the company's ability to meet Food and Drug Administration (FDA) and other
regulatory requirements for product clearances or to comply with FDA and other
regulatory regulations or procedures; the ability to make strategic
acquisitions and to successfully integrate the acquired operations into the
company's business; the company's ability to protect the company's
intellectual property; the potential loss of key distributors or key
personnel; challenges to public tender awards; and the other risks listed from
time to time in the company's filings with the Securities and Exchange
Commission, which by this reference are incorporated herein. The company
assumes no obligation to update or revise the forward-looking statements in
this release because of new information, future events, or otherwise.

A summary of earnings and other financial information follows.

Varian Medical Systems, Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(Unaudited)

(Dollars and shares in
millions, except Q4 QTR Q4 QTR Q4 YTD Q4 YTD
per share amounts) 2009 2008 2009 2008
------ ------ ------ ------
Net orders $755.3 725.3 2,380.6 2,302.1
Oncology Systems 569.6 610.5 1,890.7 1,870.7
X-Ray Products 97.0 94.2 339.1 336.8
Other 88.7 20.6 150.8 94.6
Order backlog $2,054.4 1,887.8 2,054.4 1,887.8
Revenues $642.0 592.7 2,214.1 2,069.7
Oncology Systems 526.8 482.6 1,797.8 1,671.8
X-Ray Products 92.6 83.1 331.7 305.2
Other 22.6 27.0 84.6 92.7
Cost of revenues $357.1 330.2 1,253.6 1,192.2
Gross margin 284.9 262.5 960.5 877.5
As a percent of revenues 44.4% 44.3% 43.4% 42.4%
Operating expenses
Research and development 38.1 39.1 147.4 135.6
Selling, general and
administrative 96.2 87.8 339.0 322.5
Operating earnings 150.6 135.6 474.1 419.4
As a percent of revenues 23.5% 22.9% 21.4% 20.3%
Interest income/(expense), net (0.2) 2.2 0.5 6.6

Earnings from continuing
operations before taxes 150.4 137.8 474.6 426.0
Taxes on earnings 53.2 50.7 143.1 130.7
Earnings from continuing
operations 97.2 87.1 331.5 295.3
As a percent of revenues 15.1% 14.7% 15.0% 14.3%
Loss from discontinued
operations - net of taxes
(1) (0.2) (8.6) (12.5) (15.8)
Net earnings $97.0 78.5 319.0 279.5
------------ ----- ---- ----- -----

Net earnings (loss) per share -
basic:
Continuing operations $0.78 0.70 2.67 2.37

Discontinued operations
(1) - (0.07) (0.10) (0.13)
--- ----- ----- -----
Net earnings per share $0.78 0.63 2.57 2.24
Net earnings (loss) per share
- diluted:
Continuing operations $0.78 0.68 2.65 2.31

Discontinued operations
(1) (0.01) (0.06) (0.10) (0.12)
----- ----- ----- -----
Net earnings per share $0.77 0.62 2.55 2.19

Shares used in the
calculation of net earnings
per share: ( )
Average shares outstanding -
basic 124.3 124.5 124.0 124.8
Average shares outstanding -
diluted 125.3 127.4 125.0 127.6

(1) The operating results of ACCEL research instruments are classified as
discontinued operations for all periods presented.

Varian Medical Systems, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets

(In thousands) October 2, September 26,
------------- 2009 2008(2)
(Unaudited)
----------- ------------
Assets
Current assets
Cash and cash
equivalents $553,529 $397,306
Accounts receivable,
net 580,918 486,310
Inventories 321,861 282,980
Deferred tax assets and
other 216,143 209,006
Current assets
of discontinued
operations (1) - 18,799
--- ------
Total current assets 1,672,451 1,394,401
--------- ---------

Property, plant and
equipment 527,135 452,576
Accumulated
depreciation and
amortization (263,075) (234,393)
-------- --------
Property, plant and
equipment, net 264,060 218,183
------- -------

Goodwill 210,346 209,146
Other assets 161,391 150,694
Long term assets of
discontinued
operations (1) - 3,088
--- -----
Total assets $2,308,248 $1,975,512
========== ==========

Liabilities and
Stockholders' Equity
Current liabilities
Accounts payable $116,093 $105,281
Accrued expenses 304,402 252,915
Deferred revenues 130,588 141,368
Advance payments from
customers 226,964 201,783
Product warranty 50,823 51,141
Short-term borrowings 4,445 -
Current maturities of
long-term debt 9,005 7,987
Current
liabilities of
discontinued
operations (1) - 21,202
--- ------
Total current
liabilities 842,320 781,677
Other long-term
liabilities 130,751 134,251
Long-term debt 23,394 32,399
------ ------
Total liabilities 996,465 948,327
------- -------

Stockholders' Equity
Common stock 125,281 125,590
Capital in excess of
par value 516,478 468,384
Retained earnings and
accumulated other
comprehensive loss 670,024 433,211
------- -------
Total stockholders'
equity 1,311,783 1,027,185
--------- ---------
Total liabilities and
stockholders' equity $2,308,248 $1,975,512
========== ==========

(1) The assets and liabilities of ACCEL research instruments are
classified as discontinued operations.
(2) The condensed consolidated balance sheet as of September 26,
2008 was derived from audited financial statements as of that date.

FOR INFORMATION CONTACT:
Elisha Finney (650) 424-6803
elisha.finney@varian.com

Spencer Sias (650) 424-5782
spencer.sias@varian.com

SOURCE Varian Medical Systems

Elisha Finney, +1-650-424-6803, elisha.finney@varian.com, or Spencer Sias,
+1-650-424-5782, spencer.sias@varian.com, both of Varian